Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness and safety of repeat dose subcutaneous ketamine for treatment-resistant depression, and the impact of prior ketamine treatment: open label extension of the KADS study.

The British journal of psychiatry : the journal of mental science·2026
Same author

Patient out-of-pocket costs for antihypertensive single pill combination products with cost caps.

Journal of human hypertension·2026
Same author

A meta-analysis of the long-term effects of antihypertensive therapy on the risk of major cardiovascular disease across 51 randomized trials.

Nature medicine·2026
Same author

Adverse Effects and Treatment Discontinuation of Blood Pressure-Lowering Drugs and Combinations: A Network Meta-Analysis.

JAMA·2026
Same author

Blood pressure lowering for the prevention of REcurrent stroke and Cardiovascular outcomes After acute intracerebral haemorrhage: protocol for an individual Participant data meta-analysis of randomised controlled trials (RECAP-ICH).

Cerebrovascular diseases (Basel, Switzerland)·2026
Same author

Efficacy and Safety of Simultaneous Initiation of SGLT2 Inhibitors and Mineralocorticoid Receptor Antagonists in Patients With Chronic Kidney Disease or Heart Failure: A Systematic Review and Meta-Analysis.

JACC. Heart failure·2026

Related Experiment Video

Updated: Jul 3, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Chitosan for overweight or obesity.

Andrew B Jull1, Cliona Ni Mhurchu, Derrick A Bennett

  • 1Clinical Trials Research Unit, University of Auckland, Private Bag 92019, Auckland, New Zealand. a.jull@ctru.auckland.ac.nz

The Cochrane Database of Systematic Reviews
|July 23, 2008
PubMed
Summary

Chitosan may offer short-term weight loss benefits for overweight individuals, but high-quality studies show minimal clinical significance. Further research is needed to confirm its efficacy and safety for obesity treatment.

More Related Videos

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum (Clove) and Cuminun cyminum (Cumin) on C57BL6/j Mice Fed High-Fat Diet
13:09

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum (Clove) and Cuminun cyminum (Cumin) on C57BL6/j Mice Fed High-Fat Diet

Published on: July 31, 2021

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

Related Experiment Videos

Last Updated: Jul 3, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum (Clove) and Cuminun cyminum (Cumin) on C57BL6/j Mice Fed High-Fat Diet
13:09

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum (Clove) and Cuminun cyminum (Cumin) on C57BL6/j Mice Fed High-Fat Diet

Published on: July 31, 2021

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

Area of Science:

  • Nutritional Science
  • Pharmacology
  • Public Health

Background:

  • Chitosan, a derivative of chitin, is a widely available dietary supplement.
  • It is purported to aid in body weight reduction.
  • However, its effectiveness for weight management remains debated despite numerous studies.

Purpose of the Study:

  • To systematically evaluate the efficacy of chitosan as an intervention for overweight and obesity.
  • To synthesize evidence from randomized controlled trials to determine the clinical significance of chitosan's effects.

Main Methods:

  • A comprehensive literature search was conducted across major electronic databases and specialized websites.
  • Randomized controlled trials (RCTs) of at least four weeks duration in overweight or obese adults were included.
  • Data extraction and analysis were performed independently by two reviewers, with pooled effect sizes calculated using the inverse variance method.

Main Results:

  • Fifteen RCTs with 1219 participants were analyzed.
  • Chitosan showed a statistically significant, though modest, reduction in body weight (-1.7 kg) compared to placebo.
  • Significant decreases in total cholesterol and blood pressure were also observed, with no significant difference in adverse events or fecal fat excretion.

Conclusions:

  • Chitosan demonstrates some short-term efficacy over placebo for weight management in overweight and obese individuals.
  • However, the overall quality of many trials is suboptimal, leading to variable results.
  • High-quality evidence suggests that chitosan's impact on body weight is minimal and likely not clinically significant.